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Abstract: The protozoan parasites Trypanosoma brucei, Trypan-
osoma cruzi and Leishmania spp. are responsible for the severely
debilitating neglected Tropical diseases of African sleeping sick-
ness, Chagas disease and leishmaniasis, respectively. As part of
our ongoing programme exploring the potential of simplified
analogues of the acetogenin chamuvarinin we identified the
T. brucei FoF1-ATP synthase as a target of our earlier triazole
analogue series. Using computational docking studies, we hy-
pothesised that the central triazole heterocyclic spacer could
be substituted for a central 2,5-substituted furan moiety, thus
Introduction
Infectious parasitic diseases are one of the major concerns in
Developing countries. In particular, the protozoan parasites of
the kinetoplastid family are responsible for several debilitating
diseases, with Trypanosoma brucei, Trypanosoma cruzi and Leish-
mania spp. being responsible for African sleeping sickness (hu-
man African trypanosomiasis, HAT), Chagas disease (American
trypanosomiasis), and leishmaniasis, respectively.[1–3] All three
diseases have a multi-thousand annual mortality rate, but have
been inadequately investigated, mainly due to the limited fi-
nancial incentive in treating these conditions. The existing treat-
ments have severe side effects and are difficult to administer
(usually intravenously) given the challenging healthcare infra-
structure in many affected countries.[4–7] A number of novel
candidate molecules have entered clinical trials, Fexinidazole[8,9]
and SCYX-7158[10] currently being in phase II/III trials. Neverthe-
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diversifying the chemical framework for the generation of com-
pounds with greater potency and/or selectivity. Here we report
the design, docking, synthesis and biological evaluation of new
series of trypanocidal compounds and demonstrate their on-
target inhibitory effects. Furthermore, the synthesis of furans by
the modular coupling of alkyne- and aldehyde-THPs to bis-THP
1,4-alkyne diols followed by ruthenium/xantphos-catalysed
heterocyclisation described here represents the most complex
use of this method of heterocyclisation to date.
less, emerging resistance towards existing treatments[11–13]
combined with the lack of preventive methods or possibility
for vaccination,[14–16] indicate an urgent need for novel, broad-
spectrum and selective trypanocidal treatments, particularly in
the light of the ambitious target set by the World Health Orga-
nisation (WHO) to eradicate HAT by 2020.[1]
Natural products are a valuable source of unexplored chemi-
cal frameworks for the development of new drugs. Chamuvari-
nin (1), originally isolated from the roots of Uvaria chamae,
which has traditionally been used as a herbal remedy for HAT,
and subsequently synthesised in our laboratory,[17] has low mi-
cromolar trypanocidal activity (Figure 1).[18] We have since de-
scribed a series of bis-tetrahydropyran 1,4-triazole analogues
based on the chamuvarinin polyether core and assembled from
a pool of readily accessible chiral tetrahydropyran (THP) build-
ing blocks linked by different heterocyclic spacers including 1,4-
triazoles of type 2 (Figure 1). Many of these simplified ana-
logues displayed low micromolar trypanocidal activities but
more significantly excellent selectivities relative to mammalian
cell lines.[19–22]
Through a series of pull-down experiments we identified the
T. brucei FoF1-ATP synthase as a target for our lead triazole
series.[23] FoF1 is a highly conserved mitochondrial protein con-
sisting of transmembrane (Fo) and matrix-facing (F1) moie-
ties.[24,25] F1, which binds our triazole inhibitors, is a hetero-
hexamer consisting of alternating α- and -subunits with six
nucleotide-binding sites at their interfaces, three of which are
catalytic and primarily constitute residues from the -subunits,
while the remaining three comprising mostly α-subunit resi-
dues have a regulatory function. From our identification and
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Figure 1. Trypanocidal chamuvarinin, simplified heterocyclic analogues and
structure of DB75.
verification of F1 as a target, we proposed that our compounds
act as ADP mimics and bind at these nucleotide-binding sites.
We hypothesised that the triazole spacer unit in our earlier
generation inhibitor series (of type 2, Figure 1) could be substi-
tuted for a 2,5-subsitituted furan moiety, of type 3, and that
this alteration to the chemical framework would reduce confor-
mational flexibility across the heterocyclic array, while maintain-
ing or offering greater potency and/or selectivity. Such bis-tet-
rahydropyran 2,5-substituted furan compounds share a degree
of structural similarity with DB75, a bis-phenyl 2,5-furan di-
amidine, which is also reported to inhibit the trypanosomatid
FoF1-ATP synthase.[26] Herein we undertook computational
docking of furans into the recently disclosed crystal structure
of F1 from T. brucei[25] to identify compounds with potential
trypanocidal activities. We then undertook the synthesis of a
targeted library of stereochemically complex furan derivatives
identified as potential enzyme binders and assessed their bio-
logical potential in cytotoxicity assays and F1 assays to confirm
their on-target activities.
Results and Discussion
To confirm that AutoDock Vina had been set up correctly, and
to estimate binding affinity in kcal/mol, ADP and ATP were
docked into the catalytic site (corresponding to the ATP-bound
conformation) of F1 from T. brucei.[25,27] Both compounds
docked suitably close to the position of ADP detected within
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the F1 crystal structure (Figure 2A–B), although the -phos-
phate was positioned where the γ-phosphate of ATP would nor-
mally reside, rather than in its own pocket. This is likely a result
of Mg2+ and water molecules in the crystal structure, which
help coordinate the -phosphate within its phosphate-binding
pocket, being absent from the docking calculations (since inhib-
itors can often displace ions to increase binding affinities). On
this basis we were satisfied that our modeling methodology
had been setup appropriately.
We next docked our lead triazole 4, which we have estab-
lished as an F1 inhibitor,[23] into the same catalytic site of F1
from T. brucei. Triazole 4 docked in the same mode as that
predicted for bovine F1,[23] with the THP-Et side chain bound
within the hydrophobic adenine-binding pocket and the THP-
OH interacting with Glu194, Arg195 and Ser'357 (the prime de-
noting a residue from the α-subunit) within the γ-phosphate-
binding pocket (Figure 2C). This binding mode was predicted
to have a similar affinity for the receptor as the substrate and
product (Table 1) despite possessing many fewer atoms capable
of forming hydrogen bonds than ADP/ATP. However, only the
phosphates of ADP and ATP actually form hydrogen bonds with
the receptor; the adenine only forms hydrophobic interactions
(with Tyr350, Phe429, Val170 and Thr430) while the ribose acts
as a heterocyclic linker, thus triazole 4 is able to mimic the
substrate(s).
The bis-tetrahydropyran furan 5 was designed as an ana-
logue of our lead triazole 4 and alternative substrate mimetic.
Both 4 and 5 contain THP-Et and THP-OH moieties fused by a
heterocycle, but the different orientation of the furan linker
could provide alternative stereochemistry for further derivatisa-
tion and improved inhibitor design. Docking of furan 5 revealed
that it is likely to adopt a similar binding position to triazole 4
in the catalytic site, with the THP-Et buried within the hydro-
phobic adenine-binding pocket and the free alcohol forming
hydrogen bonds with Glu194, Arg195 and Ser'357 in the γ-
phosphate-binding pocket (Figure 2D). Furthermore, the pre-
dicted affinity was similar to that of 4 (Table 1).
We postulated that the substitution of the Et group for a
benzyl ether (OBn) at R2 would lead to an affinity enhancement
through the introduction of additional pi-stacking interactions
between Tyr350 and Phe429 in the adenine-binding pocket, as
occurs with ADP and ATP. Docking of 6 (Figure 2E) indicated
that the OBn fits within the adenine-binding pocket without
disrupting the binding of the free alcohol within the γ-phos-
phate-binding pocket and lead to a slight improvement in pre-
dicted binding affinity. To determine whether different THP
stereochemical permutations could optimise binding, syn-syn
(furan 7), anti-syn (furan 8) and anti-anti (furan 9) isomers were
also docked. All anchored the OBn and OH moieties within the
adenine- and γ-phosphate-binding pockets respectively and
through the conformational flexibility of the THP and furan
framework to link together (Figure 2E-H), resulting in similar
docking scores.
To determine the importance of the free alcohol on inhibitor
potency, the THP-OH was replaced with THP-OBn and resulting
bis-THP-OBn furans (furans 10, 11 and 12) were docked into
the catalytic site (Figure 2I-K). For each compound hydrogen
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Figure 2. Docked positions of compounds within the T. brucei F1 catalytic site. (A) Position of bound ADP coordinated with ions in the crystal structure. (B)
Docked position of ADP in the absence of coordinating ions. The phosphates occupy a slightly different position, but the ribose and adenine occupy the
same positions as in the crystal structure. C-L colour scheme yellow, syn-syn; green, syn-anti; cyan, anti-syn; magenta, anti-anti. (C-D) Docking of lead triazole
4 with Et at R1 and OH at R2 and furan analogue 5. The R2 OH forms interactions with the phosphate-binding pocket. (E-H) Furan 6–9 with OBn at R1 and
OH at R2. The additional R1 OBn allows π-stacking in the adenine-bonding pocket. (I-K) Bis-OBn furans 10–12. Substitution of the R2 OH for OBn results in
the loss of all H-bonds and potential destabilisation of bound compound. (L) Furan 13, with the OBn at R1, flips orientation indicating the phenyl is preferable
in the adenine pocket.
Table 1. Compound stereochemistries and docking scores.
Architecture Dock affinity Figure
R1 THP THP R2 (kcal/mol)
ADP – – – – –9.5 2A,B
ATP – – – – –9.8 –
Triazole 4 Et Syn Syn OH –9.0 2C
Furan 5 Et Syn Anti OH –8.9 2D
Furan 6 OBn Syn Anti OH –9.7 2E
Furan 7 OBn Syn Syn OH –9.7 2F
Furan 8 OBn Anti Syn OH –9.1 2G
Furan 9 OBn Anti Anti OH –9.9 2H
Furan 10 OBn Syn Syn OBn –9.6 2I
Furan 11 [a] OBn Syn Anti OBn –9.7 2J
Furan 12 OBn Anti Anti OBn –8.7 2K
Furan 13 Et Syn Anti OBn –9.4 2L
[a] Furan 11 can also be represented as OBn-Anti-Syn-OBn.
bonding with Glu194, Arg195 and Ser'357 in the γ-phosphate-
binding pocket was completely lost, and despite scoring well
in docking, the bound conformations appeared unrealistic, with
most of the hydrophobic contacts appearing as intramolecular
interactions rather than interactions with the receptor.
As the presence of the OBn at R1 in addition to the OBn at
R2 may make the molecules too large to fit comfortably into
the active site, we docked 13 with an OBn at R1 and a smaller
Et at R2 (Figure 2L). Due to the relative similarity of furan core
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architectures, 13 flipped within the binding site with the OBn,
rather than the THP-Et, docking in the adenine-binding pocket.
The docked position of 13 was similar to that of furans 6–9 with
OBn at R1 instead of R2. This would suggest that the phenyl at
R2 is likely to improve inhibitor binding over the THP-Et motif
of compounds 4 and 5. Given the promising docking results for
our furan compounds with free alcohols, we decided to synthe-
sise these select examples for biological evaluation, along with
the bis-THP-OBn compounds as negative controls.
Synthesis of 2,5-Substituted Furan Inhibitors
The classical syntheses of furans commonly utilise 1,4-dicarb-
onyl precursors,[28,29] such compounds are often challenging to
access with limited capacity to vary precursor substitution.
Hence, multiple methodologies of heterocyclic ring formation
have been developed utilising dicarbonyl alternatives, such as
allenes,[30–35] alkynyl epoxides,[35] alkynyl ketones[36] or 1,4-alk-
yne diols.[37] The methodology introduced by Williams and co-
workers involving the ruthenium/xantphos-catalysed heterocy-
clisation of 1,4-alkyne diols[38] avoids the isolation of challeng-
ing 1,4-diketone precursors which was particularly attractive in
our current system to access furans of type 14, given the sensi-
tivity of α-oxygenated carbonyl groups to epimerisation and
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the compatibility with our readily accessible chiral THP building
blocks of type 15 (Scheme 1).[17,18]
Scheme 1. Bis-tetrahydropyran 2,5-furan retrosynthesis.
Starting from our established THP building block syn-16 and
anti-17,[17,19] Swern oxidation followed by diastereoselective
Carreira alkynylation[39–41] gave the corresponding propargyl al-
cohols 18 and 19, respectively. While the stereochemical con-
Scheme 3. Alkyne coupling and ruthenium/xantphos-catalysed heterocyclisation to furans: a) (i) alkyne, nBuLi, MTBE, –78 °C, 10 min; aldehyde, –78 to r.t., 1 h;
(ii) (±)-CSA, MeOH/CH2Cl2 (1:1), r.t., 15 h; (b) Ru(PPh3)3(CO)H2 (6 mol-%), xantphos (6 mol-%), PhCO2H, PhMe, 120 °C, sealed tube, 15 h. aInitially co-isolated
with aldehyde by-product, upon reduction with NaBH4 in MeOH furan 7 was isolated in 11 % yield over two steps; b32 was isolated in 49 % yield after
two cycles of (±)-CSA in MeOH/CH2Cl2 (1:1), see supporting information. MTBE = methyl tert-butyltether, (±)-CSA = camphorsulfonic acid, xantphos = 4,5-
bis(diphenylphosphanyl)-9,9-dimethylxanthene.
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Scheme 2. Synthesis of THP-alkynes 20 and 21: a) (COCl)2, DMSO, CH2Cl2,
–78 °C, 1 h; then Et3N –78 °C to r.t., 2 h; b) TMSCCH, Zn(OTf)2, (+)-N-methyle-
phedrine, Et3N, PhMe, 70 °C, 16 h; c) (i) K2CO3, MeOH, r.t. 5 h; (ii) TBSCl,
ImH, DMAP, CH2Cl2, r.t., 16 h. TBSCl = tert-butyldimethylsilyl chloride, ImH =
imidazole, DMAP = 4-dimethylaminopyridine.
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trol of the alkynylation reactions was inconsequential for the
downstream synthesis, these conditions proved more efficient
compared with lithium TMS-acetylide addition to the respective
aldehydes.[42–45] The alkynylation products were then treated
with potassium carbonate to cleave the C-TMS group and pro-
tected as their respective TBS ethers in alkynes 20 and 21
(Scheme 2).
With alkyne precursors 20 and 21 in hand along with the
ethyl-terminated variant 22 (used in our initial synthesis of
1),[17] we were in a position to begin the modular assembly of
first the key 1,4-alkyne diol framework followed by the Williams
Ru-catalysed heterocyclisation to access furan derivatives with
both diastereomeric and terminal functionality variations, as de-
tailed in Scheme 3. Access to the intermediate 1,4-alkyne diol
precursors was achieved by nBuLi deprotonation of the respec-
tive alkyne 20, 21 or 22 followed by addition of the respective
THP-aldehyde 23–26 to give precursors 27–35 (entries 1–9)
after silyl group cleavage in modest but workable yields over
two steps. In the case of additions to syn-THP aldehydes (entries
1, 2 and 9) the products were formed with low diastereoselecti-
vity at the new carbinol centre which proved inconsequential
in the subsequent cyclisation. In contrast the addition of alk-
ynes to anti-THP aldehydes (entries 3–8) proceeded with high
levels of Felkin-Anh selectivity (>95:<5 d.r. in all cases). The in-
termediate alkyne 1,4-diols where then cyclised under the con-
ditions described by Williams and co-workers employing the
Ru(PPh3)3(CO)H2/xantphos catalyst combination to afford the
2,5-disubstituted furan derivatives 5–13, as detailed in
Scheme 3. The yields for this isomerisation varied from low to
modest, given the complexity of the 1,4-alkyne diol precursors,
in terms of α-oxygenated tetrahydropyran motifs flanking the
central 1,4-alkyne diol. However, in all cases sufficient material
was isolated to facilitate evaluation of antitrypanosomatid activ-
ity.
Biological Evaluation
Synthesised furans were tested in cytotoxicity assays against a
panel of kinetoplastid cell lines including bloodstream form
(BSF) T. brucei, procyclic form (PF) T. brucei, epimastigote form
T. cruzi and promastigote form L. major, as well as human HeLa
cells for the determination of cell selectivity. EC50 values for 5,
Table 2. Biological activities of compounds.
Entry Compound EC50 [μM] SI [a] % ATP
T. brucei BSF T. brucei PF T.cruzi L.major HeLa inhibition
1 Triazole 4 1.8 ± 0.1 8.4 ± 0.2 ND ND 7.0 ± 1.0 4 124 ± 24
2 Furan 5 12.2 ± 0.8 10.8 ± 0.3 28.9 ± 1.4 17.6 ± 0.9 11.3 ± 1.13 1 163 ± 11
3 Furan 6 9.7 ± 0.7 7.2 ± 0.2 24.9 ± 1.1 29.5 ± 1.8 7.9 ± 0.3 1 135 ± 13
4 Furan 7 10.9 ± 0.4 12.2 ± 0.4 30.8 ± 0.7 14.3 ± 0.3 34.4 ± 2.2 3 148 ± 19
5 Furan 8 14.3 ± 0.6 5.0 ± 0.1 18.0 ± 1.0 17.6 ± 0.6 9.1 ± 1.4 1 137 ± 17
6 Furan 9 9.6 ± 1.3 5.1 ± 0.3 21.3 ± 1.4 25.4 ± 1.0 7.9 ± 1.5 1 134 ± 27
7 Furan 10 29.9 ± 3.1 39.0 ± 1.2 >500 >500 >500 >17 –33 ± 21
8 Furan 11[b] 23.2 ± 1.1 70.3 ± 3.2 >500 >500 >500 >22 –22 ± 31
9 Furan 12 14.9 ± 0.6 32.2 ± 2.1 >500 >500 >500 >34 12 ± 6
10 Furan 13 44.0 ± 3.4 77.3 ± 2.9 127 ± 10 >500 >250 >6 ND
[a] SI (selectivity index) is the ratio of HeLa EC50/BSF EC50 and measures how selective compounds are towards BSF T. brucei relative to human HeLa cell line.
[b] Furan 11 can also be represented as OBn-anti-syn-OBn.
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the furan analogue of our lead triazole 4, were similar across all
cell lines (Table 2, entries 1 and 2), ranging from 10.8–28.9 μM,
and were not dissimilar from 4. To confirm that 5 was acting
on target, we assessed the ability of the compound to inhibit F1
ATP production in digitonin-permeabilised PF T. brucei, which
contained permeable cell membranes but intact, functional mi-
tochondria. Like triazole 4, furan 5 ablated ATP production
(Table 2, entry 2), confirming that its trypanocidal activity is
through F1 inhibition, supporting docking predictions that both
compounds would be similar. These data demonstrated that
the central 1,4-triazole heterocyclic spacer could indeed be sub-
stituted for a 2,5-furan moiety.
Likewise, the F1 assay confirmed that OBn-substituted furans
6, 7, 8 and 9 also acted on target, by eliminating F1 ATP pro-
duction (Table 2, entries 3–6). Cytotoxicity assays revealed that
all four compounds had similar potencies across all cell lines
tested, ranging from 5.0–34.4 μM, but disappointingly, no com-
pound offered improved toxicity or selectivity over the THP-Et
analogue 5 (Table 2, entry 2), despite the introduction of π-
stacking interactions within the adenine-binding pocket. It is
possible that the enhancement in binding through π-stacking
does not outweigh the potential loss in affinity created through
increased inhibitor flexibility, and future studies will investigate
the removal of a THP to mitigate this.
Testing of the bis-THP-OBn furans 10, 11 and 12 against F1
revealed that, as expected, they did not inhibit F1 ATP produc-
tion (Table 2, entries 7–9), and compounds were ineffective
against T. cruzi, L. major and HeLa cells, failing to significantly
inhibit cell growth below 250 μM. This correlation between loss
of activity against F1 and against cells by furans 10–12 implies
that in these cells, compounds 4–9 induce their cytotoxic activi-
ties through F1 inhibition. Given that mammalian and T. brucei
F1 are highly similar[24,25] and that 4–9 are relatively non-spe-
cific towards trypanosomatid cells, the design of trypanosoma-
tid-specific F1 inhibitors of this type may prove challenging.
Remarkably, despite failing to inhibit T. brucei F1, 10, 11 and
12 still displayed activity towards T. brucei, albeit with some-
what reduced potencies (Table 2, entries 7–9), providing com-
pounds with selectivities towards BSF T. brucei over human
HeLa cells of >17, >22 and >34 respectively. This would suggest
that these bis-THP-OBn compounds have an alternative T. bru-
cei-specific target and that in the design of potential F1-target-
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ting inhibitors, variants incapable of F1 inhibition have proven
fruitful. Future compounds will likely be designed for their
inability to inhibit F1 in order to reduce their potent side effects.
Furan 13, which docks in a flipped orientation providing an
anti-syn architecture, like furans 8 and 11, but with the OH/OBn
substituted for an Et group, also failed to significantly inhibit
the growth of HeLa, L. major and T. cruzi (Table 2, entry 10) and
both displayed cytotoxicity similar to 11. This further highlights
the importance of hydrogen bonding to the γ-phosphate-bind-
ing pocket for F1-binding and inhibition and may therefore
form a focal point for avoidance in future investigations.
Conclusions
Having previously identified the target of our original triazole
inhibitor series as mitochondrial F1 and established their hypo-
thetical binding mode, furan analogues were proposed to pro-
vide an alternative framework for future analogue derivatisa-
tion. We therefore employed a structure-based approach to de-
sign, synthesise and biologically evaluate compounds targeting
the FoF1-ATP synthase. Computational docking indicated that
binding of furan analogues was feasible, so the compounds
were synthesised by the coupling of pairs of THP building
blocks to access 1,4-alkyne diols, followed by ruthenium/
xantphos-catalysed heterocyclisation. This successful synthetic
route is itself an achievement given the complexity of the alk-
yne diol precursors, which to the best of our knowledge, are
the most complex substrates thus described for this method of
heterocyclisation. Cytotoxicity assays confirmed that many of
the synthesised furans were broadly cytotoxic against a panel
of kinetoplastid pathogens as well as human HeLa cells, while
an F1 ATP synthase assay confirmed that they acted on target
at F1. Docking indicated that substitution of the THP-Et (5) for
THP-OBn (6–9) could potentially enhance inhibitor binding
through favourable π-stacking interactions with the receptor,
and while all retained F1-inhibitory properties, enhanced cyto-
toxicity was not evident. Inhibitors with terminal hydroxylation
appeared to form critical hydrogen bonding interactions. Upon
substitution with a benzyl ether moiety a loss of activity against
most cell lines was observed along with the loss of F1 inhibi-
tion, further indicating the on-target effects of previous ana-
logues. Unexpectedly, these di-benzoylated compounds 10, 11
and 12 retained modest activity against T. brucei, with selectivi-
ties ranging from 17–34 fold, and therefore represent new lead
compounds for further development in finding new treatments
for HAT.
Experimental Section
Compound synthesis and characterisation
Full details of compound synthesis and spectroscopic characterisa-
tion is available in the supporting information.
Computational Studies
Compounds – bis-THP furan compounds of syn-syn, syn-anti, anti-
syn and anti-anti variants and 4 were drawn and converted to three-
dimensional Protein Data Bank (PDB) format structures and mini-
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mised using Schrødinger Suite 2012 update 2 (Maestro version
9.3.518) with Macromodel using the MMFF forcefield. PDB coordi-
nates of ADP and ATP were extracted directly from F1. Compounds
were then converted to pdbqt format using AutodockTools version
1.5.6.[46]
Protein receptor sites – the F1 crystal structures from T. brucei
(6F5D.pdb)[25] was used for docking with Autodock Vina.[27] The
receptor was prepared exactly as described in the user manual us-
ing Autodock tools.[46] A grid box of 17 × 15 × 23 Å was centred
around the catalytic site comprising chains B (α-subunit) and F (-
subunit).
Compound docking and evaluation – Ligand-macromolecule dock-
ing was carried out using Autodock Vina. In the same directory
files for the ligand and macromolecule, configuration file, and the
vina.exe file available for free online were placed. The top 10 bind-
ing modes were output and visually assessed with Pymol (Schrø-
dinger). Optimal binding mode and corresponding AutoDock en-
ergy (kcal/mol) for each compound were assessed.
Biological Evaluation
Compounds were screened against parasites (bloodstream form
[BSF] T. brucei brucei strain 427, procyclic [PF] form T. brucei strain
29–13, epimastigote T. cruzi strain CL Brener, promastigote L. major
strain Friedlin) and human HeLa cells.
General cell culture – BSF T. brucei were maintained between 103-
106 cells/mL in full HMI-11 (HMI-11 medium supplemented with
10 % heat-inactivated foetal bovine serum (HI-FBS, Gibco), 1 mM
sodium pyruvate, 160 μM thymidine, 50 μM Bathcupromedisulfonic
acid, 1 mM hypoxanthine, 1.5 mM L-cysteine, 60 μM 1-thioglycerol,
and 2.5 mg/L G418 (Calbiochem)) at 37 °C with 5 % v/v CO2, as
described previously.[47] PF T. brucei were maintained between
105-107 cells/mL in full SDM-79 (SDM-79 medium supplemented
with 10 % HI-FBS, 23.8 mM sodium bicarbonate, 10 μM haemin,
12.5 mg/L G418 and 25 mg/L hygromycin) at 28 °C with 5 % CO2.[48]
T. cruzi were maintained between 106-107 cells/mL in full RTH (RPMI
1640 medium supplemented with 10 % HI-FBS, 16.53 mM HEPES
pH 7.2, 4.2 g/L peptone (Fluka), 2 mM sodium glutamate, 100 mg/
L streptomycin, 100 KU/L penicillin, 30 μM haemin) at 28 °C with
5 % CO2. L. major were maintained between 105-107 cells/mL in
full M199 (M199 medium (Sigma) supplemented with 10 % HI-FBS,
4.17 mM sodium bicarbonate, 40 mM HEPES pH 7.4, 100 μM adeno-
sine and 10 μM haemin) at 28 °C with 5 % CO2. HeLa cells were
maintained in DMEM supplemented with 10 % HI-FBS at 37 °C with
5 % CO2.
Cytotoxicity assays – compounds were serially diluted across 96-well
microtitre plates containing 100 μL of relevant full growth medium
in quadruplicate. The final concentration of DMSO (used to solubil-
ise compounds) never exceeded 1 % (v/v). Cells were diluted to 2 ×
required cell density in relevant full growth medium and 100 μL
added to the 100 μL serial dilution (total volume 200 μL per well),
generating starting cell densities of 5 × 103/mL (BSF T. brucei),
5 × 104/mL (PF T. brucei, promastigote L. major and HeLa) or
1 × 106/mL (epimastigote T. cruzi). Cultures were incubated at the
relevant temperature with 5 % CO2 for 64 hours, then 10–20 μL of
resazurin (1.1 mg/mL in PBS) was added and cultures were incu-
bated for a further 6 h at relevant temperature with 5 % CO2 to
allow cells to oxidise resazurin to resorufin. Resorufin fluorescence
was recorded with a Bio Tek FLX8000 spectrofluorimeter and Gen5
software, using an excitation of 545 ± 15 nm and emission of
590 nm. Curves were calculated using GraFit through the applica-
tion of four-parameter least squared non-linear regression and EC50
Full Paper
values were taken as the concentration of drug at the inflection
point.
FoF1 ATP synthase inhibition assay
Compounds were screened for their abilities to inhibit ATP produc-
tion from succinate in digitonin-permeabilised PF T. brucei as de-
scribed previously.[23] Briefly, PF T. brucei were washed in PBS, resus-
pended in isotonic SoTE buffer (20 mM Tris·HCl pH 7.5, 2 mM EDTA
pH 7.5, 600 mM sorbitol) and their plasma membranes permeabil-
ised with 0.015 % (w/v) digitonin for 5 min on ice. Permeabilised
cells were pelleted at 5000 g for 3 min at 4 °C, resuspended in
isotonic assay buffer (20 mM Tris·HCl pH 7.4, 15 mM KH2PO4, 10 mM
MgSO4, 600 mM sorbitol, 2.5 mg/mL fatty acid-free BSA), and incu-
bated with/without inhibitor at 200 μM for 10 min at r.t. to allow
inhibitors to take effect. Succinate (2.5 mM) was added as substrate
and incubated at r.t. for 10 min to allow uptake to the mitochon-
drion. ATP production was initiated with the addition of 60 μM ADP,
and after 30 min incubation at r.t. the reaction was terminated with
the addition of 1.37 % (final concentration) perchloric acid, which
also released generated ATP from the mitochondrion. After neutrali-
sation with KOH, the degree of ATP production was quantified using
the CLSII bioluminescence assay kit (Roche) as directed, recording
bioluminescence using Spectramax Gemini XPD spectrofluorimeter
(Molecular Devices) and Softmax Pro software. Background lumines-
cence was subtracted from each well and ATP levels calculated rela-
tive to uninhibited controls.
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